EUVIMEDAtrasti EUVIMED
CrossrefInformacijos kortelė

Retrospective Evaluation of the Quick Sequential Organ Failure Assessment (qSOFA) Score as a Prognostic Indicator in Dogs With Systemic Inflammatory Response Syndrome (2017–2023): 112 Cases

Dongseok Kim, Jin‐Kyung Kim, Hana Kim, Sungin Lee, Won‐Jae Lee, Sung‐Ho Yun, Min Jang

Journal of Veterinary Emergency and Critical Care · 2026-11-09

DOI: 10.1111/vec.70177 ↗
SantraukaBibliografiniai duomenys

Santrauka

ABSTRACT Objective To evaluate the prognostic value of the quick Sequential Organ Failure Assessment (qSOFA) score in dogs meeting the systemic inflammatory response syndrome (SIRS) criteria. Design Retrospective study. Setting Secondary referral animal hospital. Animals A total of 112 dogs diagnosed with SIRS between 2017 and 2023 were included. Interventions None. Measurements and Main Results A total of 112 dogs meeting the SIRS criteria were included; of these, 65 (60%) died during hospitalization. In the univariable analysis, a qSOFA score ≥2 was associated with mortality ( p < 0.001). In the multivariable logistic regression analysis, qSOFA score ≥2 was not retained as an independent predictor of mortality after adjustment for other variables (odds ratio [OR]: 2.24, 95% CI: 0.71–7.06; p = 0.172). Receiver operating characteristic (ROC) curve analysis for qSOFA score ≥2 yielded an area under the curve (AUC) of 0.73 (95% CI: 0.63–0.84), with a sensitivity of 72% and a specificity of 75% for predicting mortality. Conclusion In dogs with SIRS, the qSOFA score may serve as a practical tool for initial risk stratification. Nevertheless, given its limited prognostic value when used independently, further study is warranted.

Jūsų darbui tinkamos žinios.

Nuo nemokamos pradžios ir asmeninės literatūros paieškos iki viso Research Suite.

Peržiūrėti tarifus →

Ar įtraukti visi leidėjų pilnieji tekstai?

Ne. Bibliografiniai įrašai, santraukos ir pilnieji tekstai yra skirtingas turinys. Ar pilnasis tekstas prieinamas, priklauso nuo šaltinio, Open Access ir jūsų turimų licencijų. EUVIMED planas nepakeičia papildomų leidėjų teisių.

Peržiūrėti tarifus →